* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...

Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...

People with diabetes who used semaglutide or other GLP-1 agonists were also less likely to see a provider for depression.

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Citation: Baser O, Lu Y. External control arm with real world data to assess the effect of semaglutide on chronic kidney disease risk among patients with type 2 diabetes.

SOUL: Secondary results showed that the CV benefits of oral semaglutide in people with type 2 diabetes and CV disease (CVD) and/or chronic kidney disease (CKD) appeared more pronounced in people ...

Two months ago, the FDA signed off on Ozempic to reduce the risk of worsening kidney disease and cardiovascular death in those with type 2 diabetes and CKD. That nod was backed by a trial that ...

Jankowski J, Floege J, Fliser D, Böhm M, Marx N: Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021, 143:1157-72.10.1161 ...

A groundbreaking study led by researchers from Columbia Data Analytics, Bogazici University and the City University of New York (CUNY) College of Technology, has demonstrated that semaglutide, a ...